Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

NCT03694002 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03694002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03694002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2019
Completion date
March 3, 2025
Enrollment
21 (actual)
Sites
254

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced thymic carcinoma, metastatic thymic carcinoma, recurrent thymic carcinoma, unresectable thymic carcinoma